Share

European Medicine Agency’s CHMP Grants Positive Opinion to Long-Acting Growth Hormone for Patients with Pediatric Growth Hormone Deficiency

In November, the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of a marketing authorization for Ascendis Pharma’s lonapegsomatropin (TransCon hGH), a long-acting once-weekly, transiently pegylated somatropin that in the body releases somatropin, indicated for growth failure in children and adolescents aged from 3 years...
Share

Evolution of Diabetes Management: The Patient-Provider Relationship, Accessing Resources, and Surmounting Obstacles

100_Years_of_Insulin_Logo During insulin’s first century, treatments and resources for people with diabetes have steadily progressed. So, too, have relationships between the patient and the provider. A recent Endocrine Society-hosted roundtable highlighted this vital connection and how it has evolved through the decades. Leonard Thompson was 14 years old in 1922, and he was dying of type...
Share

New App Helps Parents Identify Treatable Childhood Growth Disorders Earlier

A mobile phone app can place the accurate measurement of children’s height in the hands of parents and caregivers. Preliminary data presented at the Society for Endocrinology annual conference in Edinburgh suggests that the app could reliably identify treatable growth disorders much earlier, with significant improvements in child health. Childhood growth is a strong indicator...
Share

Phase 3 Trial Shows Lonapegsomatropin Is Superior to Somatropin in Treatment-Naïve Children with Growth Hormone Deficiency

The investigational long-acting, once-weekly prodrug lonapegsomatropin (TransCon hGH) may be more beneficial to treatment-naïve pediatric patients with growth hormone deficiency (GHD) than daily somatropin of equivalent weekly dose, according to a paper recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Aimee D. Shu, MD, of Ascendis Pharma (who funded the...